# BIOEQUIVALENCE STUDY IN HEALTHY PARTICIPANTS COMPARING 4 MG AND 8 MG FESOTERODINE EXTENDED-RELEASE TABLETS (TOVIAZ™), MANUFACTURED AT ZWICKAU VERSUS FREIBURG

> **NCT04478357** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 18 (actual)

## Conditions studied

- Neurogenic Detrusor Overactivity

## Interventions

- **DRUG:** 4 mg Fesoterodine ER tablet from Zwickau
- **DRUG:** 4 mg fesoterodine ER tablet from Freiburg
- **DRUG:** 8 mg fesoterodine ER tablet from Zwickau
- **DRUG:** 8 mg fesoterodine ER tablet from Freiburg

## Key facts

- **NCT ID:** NCT04478357
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-12
- **Primary completion:** 2020-11-12
- **Final completion:** 2020-11-12
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2021-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04478357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04478357, "BIOEQUIVALENCE STUDY IN HEALTHY PARTICIPANTS COMPARING 4 MG AND 8 MG FESOTERODINE EXTENDED-RELEASE TABLETS (TOVIAZ™), MANUFACTURED AT ZWICKAU VERSUS FREIBURG". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04478357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*